InsidersTradesSigma
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
3
Disclosed sells
0
T+90 hit rate
100%
T+90 mean return
+21.5%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Bookman Michael, Directeur Juridique. Director active across 1 company, notably Immuneering Corp. Aggregated, 4 reports have been recorded. Breakdown: 3 buys · 0 sell. Total volume traded: €40k. History available since 3 August 2021. The latest transaction was filed on 15 March 2024 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations4 total
1,448 shares@ US$1.625.1% of flowClass A Common StockSEC:0001790340-24-000032:0
1,000 shares@ US$4.880.0014% mcap11.5% of flowClass A Common StockSEC:0001415889-22-005253:0
Ideal exit: 11 Feb 2023 (T+270)
1,402 shares@ US$15.000.0053% mcap44.2% of flowClass A Common StockSEC:0001104659-21-099728:0
Ideal exit: 30 Apr 2022 (T+270)
1,402 shares@ US$15.0042.0% of flowClass A Common StockSEC:0001104659-21-099728
Ideal exit: 30 Apr 2022 (T+270)
4 of 4 declarations
About Bookman Michael
Michael Bookman serves as the General Counsel and Secretary of Immuneering Corp. He is responsible for all legal matters of the company, ensuring regulatory compliance and protecting the legal interests of the organization. His expertise is essential for navigating the complex legal landscape.
